Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR PENFILL.
LEVEMIR vs LEVEMIR PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.
Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.
Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.
Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.
None Documented
None Documented
Terminal elimination half-life: 13–18 hours (up to 24 hours with large doses); reflects prolonged absorption from subcutaneous depot due to dihexyl-deamination modification.
Terminal half-life: approximately 13-14 hours (range 12-18 hours) after subcutaneous administration in patients with type 1 diabetes, reflecting prolonged absorption from the injection site. The long half-life supports once-daily dosing.
Renal: minimal, as insulin is extensively reabsorbed and degraded in the proximal tubule; hepatic metabolism: via receptor-mediated endocytosis and degradation by insulin-degrading enzyme; biliary/fecal: negligible.
Renal: negligible; metabolized by proteolytic degradation, primarily in the liver and kidneys; <1% excreted unchanged in urine. Fecal: minor.
Category C
Category C
Antidiabetic (Long-Acting Insulin)
Antidiabetic (Long-Acting Insulin)